发布时间：2006.6

摘要

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. The major product segments analyzed are Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, and Nanotubes and Fullerenes), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 91 companies including many key and niche players worldwide such as Alnis Biosciences, Inc., American Pharmaceutical Partners, Inc., Biosante Phosphate Pharmaceuticals, Inc., Capsulution NanoScience AG, Carbon Nanotechnologies, Inc, C Sixty, Inc, Dendritic Nanotechnologies, Inc., Dendritech, Inc, Elan Pharmaceuticals, Flamel Technologies, Inc, iMedd, Inc., Nanospectra Biosciences, Inc., Nanophase Technologies Corporation, Nano-C, Inc., Nanocyl SA, Nanolab Systems Ltd, Nanosphere, Inc., Nanotherapeutics, Inc., Nanosys, Inc., PSiVida Ltd, Quantum Dot Corp, Starpharma Holdings Ltd, Sigma Aldrich Company, and Triton Biosystems, Inc.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

目录及图表

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.
1. Industry Overview II-1
A Curtain Raiser II-1
What’s The Obsession With Size? II-2
Why Analysis at the Cellular Level is Important? II-2
Lessons from Nature II-3
Where Conventional Molecular Science Falls Short Nanobio
Steps In II-3
Conclusions II-3
Dawn Breaks On Nanobiotechnology II-4
Demystifying the Intriguing World of Nanobiotech II-4
Nanoparticles: The Foundation of Nanobiotechnology II-5
A Meeting Place of Medicine’s Best Solutions II-5
Challenges II-6
Nanotechnology Boom Echoes Downstream II-7
Honey, I Shrunk the World! II-7
Nanotechnology & Biology Tie the Knot: “Two to Tango” II-8
Nanobiotechnology: The Next Battlefield II-8
The Promise of Nanobiotechnology II-9
Biological Weaponries Against Diseases Come in Small Packages II-9
Proffered Benefits of Nanobiotechnology II-10
Opportunity & Beyond II-11
Nanobiotechnology
Will it Live Up to the Expectations? II-11
The Future of Nanobiotechnology: Shape of Things to Come II-12
Nanobiotechnology: The Outer Limits II-12
Futuristics: A Rumination II-12
Nanobiotechnology In the Year 2015 II-13
Field of Nanodiagnostics II-13
Field of Regenerative Medicine II-13
Field of Targeted Drug Delivery II-13

2. Market Dynamics II-14
Short Market Sizzlers II-14
Consolidation to Speed Up in Nano-Enabled Delivery Systems
Market II-14
Dearth of Blockbuster Drugs in Pipeline Sparks Interest in
Nanobio II-15
Demand for Novel Products Complements the Exuberant Outlook II-15
Public & Private Investment Pep Up the Market II-15
The Regulatory Framework Evolves with the Technology II-15
Nanomaterials & Nanoparticles Witness Robust Activity II-15
Quantum Dot Patents Pose Legal Tangles II-16
Colloidal Quantum Dots Prices Poised to Scale Down in Long Run II-16
Miniaturized Liquid Handling Becomes Progressive II-16
Unrealistic Expectations Exert Pressure On the Market II-17
High Material Costs Put a Spoke in the Market’s Growth II-17
Below Par Involvement from Pharma Biggies Limits Growth II-17
Lack of De Facto Standards: A Challenge to Reckon With II-18
Loosely Defined Safety Standards Creates a Niggling Worry II-18

3. Industry Issues, Challenges & Controversies II-19
Embroilment Over Ethical Issues II-19
Social Relevance II-19
Economic Relevance II-20
Major Challenges Confronting the Industry II-21
Commercial Exploration: A Treacherous Voyage II-21
Dendrimers Commercialization
An Uphill Task II-22
High Production Costs and Development Complexity II-22
Availability of Advanced Technology Alternatives II-22
No Defined Framework to Judge New Product’s Safety and Efficacy II-23

4. Industry Structure & Investment Patterns II-24
Industry Structure: A Quick Primer II-24
A Dissection of Select Segments II-24
Nanoparticles II-24
Nanotubes and Fullerenes II-25
Dendrimers II-25
A Peek Into the Regulatory Framework II-25
United States II-26
Europe II-26
What’s Grooming Nanobiotech into an Investment High Street? II-26
Interest Ignited by Nanotechnology II-26
Tracking Investment Patterns in Nanobiotechnology II-27
Interest in Nanobiotechnology Spills Over II-27
Patent Expiration Sends the Popularity Index Spiraling II-28
Drawing Significant Venture Capital Funds II-28
Table 1: Venture Capital Funding in Nanobiotechnology as
Compared to Other Types of Nanotechnology: A Peek into
Substantiating Numerics Taking the US Market as a
Demonstrative Example II-28
Swelling Government Grants II-29
The State of Public Sector Funding II-29
Table 2: Nanobiotechnology Market in Select Regions (2004):
Percentage Breakdown of Public Sector Funding by Country -
South Korea, Taiwan, China, Australia, Canada, and Others
(includes corresponding Graph/Chart) II-30
A Closer Look at Regional Nano Efforts II-30
United States: Unraveling the Country’s Edge II-30
Europe: Hot On the Heels of the US II-31
Germany II-31
France II-31
United Kingdom II-31
Scandinavia II-32
Table 3: European Nanobiotechnology Market (2003 & 2004):
Percentage Breakdown of Public Sector Funding by Leading
Region/Country
European Commission, Germany, France, UK,
and Others (includes corresponding Graph/Chart) II-32
Japan: A Noteworthy Region II-32

5. Nanobio’s Epochal Strides In Modern Medicine II-33
A Primer II-33
Impact on Drug Delivery Systems II-33
Benefits Offered II-34
Drug Encapsulation II-34
High Level of Specificity II-35
Increase in Drug Solubility and Uptake II-35
Greater Usage Flexibility II-35
Impact On Molecular Diagnostic Imaging II-35
Seeing The Unseen II-36
Impact On Pharmaceutical Drug Formulations II-36
Impact On Therapeutics II-37
Silver Nanoparticles as Effective Antimicrobial Agents II-37
Modern Day Nanomedicine: A Current Scenario II-38
Nanomedicine: The Cynosure of All Eyes II-38
Drug Delivery Systems Epitomized by Nanomedicine II-39
Targeted NanoDrug Delivery & Release II-40
A Peek Into Potential Nanobio Enabled Drug Carriers II-41
Micelles II-41
Liposomes II-41
Dendrimers & Liquid Crystals II-41
Nanoparticles II-41
Polymeric Nanoparticles II-42
Hydrogels II-42
Molecularly Imprinted Polymers II-42
Microelectromechanical Systems (MEMS) II-42
Nanosuspensions II-42
Fullerenes: A Platform for GenX Drug Delivery II-43
Types of Nano-Based Drug Delivery Systems, Related
Materials, and Structures II-43
Dynamics of Regenerative Medicine II-44
Tissue Engineering and Restorations II-45
Nanotechnology Enabled Diagnostics II-45
Promised Path Breaking Applications in Molecular Diagnostics
& Imaging II-46
In-Vitro Diagnostics II-47
In-Vivo Diagnostics II-47
Nanoprobes & Implantable Devices in In-vivo Imaging II-48
Nanocomposites in Molecular Labeling & Diagnostics II-48
Laboratory-on-a-Chip
A Revolutionary Technology in
Biomolecular Detection II-49
Biosensors
Heralding New Opportunities in Molecular
Diagnostics II-49
Despite Huge Potential Key Hurdles Remain in
Commercialization II-50
Magnetic Nanoparticles for Imaging Applications in MRI II-50
Dendrimers Promise Milestone Applications in MRI II-50
Conclusions II-51
Gauging the Real World Impact of Nanobiotech On Cancer: A
Case Study II-51
Quantum Dots Cock a Snook at Traditional Anti-Body Labeling
Agents II-52
Chemotherapeutic Reengineering & Gene Therapy: New
Treatment Regimes II-52
Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-53

6. Technology Overview II-54
Nanotechnology: An Introduction II-54
A Revolution in the Making II-54
Nanobiotechnology: An Exposition II-55
Nanobiotechnology & Medicine II-55
Nanobiotechnology & Biofuels II-55
Global Nanobiotechnology Market (2005): Major Products II-56
Global Nanobiotechnology Market (2005): Major Products Under
Development II-56
Analysis of Major Technology Segments II-57
Nanomaterials II-57
Nanoparticles II-57
Nanoparticles in Labeling or Bio Tagging II-58
Nanoparticles as Biomarkers II-58
Classification of Nanoparticles II-58
Solid Nanoparticles II-58
Solid Lipid Nanoparticles II-59
Calcium Phosphate Nanoparticles II-59
Dendrimers II-59
Dendrimers as Templates for Synthesis of Hybrid
Nanostructures II-59
Nanocomposites II-60
Lamellar Nanocomposites II-60
Nanostructured Materials and Membranes II-60
Nanotubes and Fullerenes II-61
Other Nanomaterials II-61
Nanoshells II-61
Nanohorns II-61
Nanocapsules II-61
Nanodevices II-62
Nanotools II-62
Select Nanotools II-62
Atomic Force Microscopes II-62
Hot Embossing Lithography II-63
Dip-Pen Nanolithography II-63

7. Global Research Centers and Institutions II-64
Centre for Biologic Nanotechnology (USA) II-64
Centre for Biological and Environmental Nanotechnology (USA) II-64
Institute of Bioengineering and Nanotechnology (Singapore) II-64
The Nanobiotechnology Center (USA) II-65
The Tyndall National Institute (Ireland) II-65

8. Research & Technology Effervescence II-66
Dendritic NanoTechnologies Develops Novel Priostar™ Dendrimer
Technology II-66
Scientists Develop Novel DNA Buckyballs for Drug Delivery
Applications II-66
Nanotechnology Creates Hopes for Artificial Kidneys II-66
Chinese Scientists Develop Novel Drug Delivery System II-66
Scientists Attach Nanograins to Iron Oxide Nanoparticles for
Drug Delivery II-67
Researchers Employ Nanotubules to Diffuse Cancer Cells II-67
Scientists Develop Innovative Nanoparticles for Cancer Treatment II-67
Nanobiotech Companies Close in on Developing Avian Flu Vaccine II-68
Silver Nanoparticles Show Promise Against HIV-1 Virus II-68
Nanoparticles Prove Highly Active Against Water Contaminants II-68
Nanobiotechnology Offers Major Breakthrough in New HIV Drug
Development II-68
Scientists Develop Innovative Nanoparticles to Treat Tumors II-69
Nano-sized Polymers Offer Key Application in Treating Tumor
Cells II-69
Carbon Nanotubes Hold Promise in Development of Synthetic
Muscular Tissues II-69
Silicon Nanowires Offer Key Solutions to Cancer Detection and
Diagnosis II-70
Antigen Loaded Nanospheres Induce Immune Response II-70
Tritons Nanotechnology Promises Potential Tool against Tumors II-70
Carbon Nanotubes for Development of Advanced Biosensors II-71
Scientists Develop New Technology to Produce Gold and Silver
Nanoparticles II-71
Scientists Develop Optical Biosensors from Single- Walled
Carbon Nanotubes II-71
Layer-by-Layer Nanoassembly Method for Nanocapsule Synthesis
Gets Underway II-71
Nanowires Prove Effective in Viruses Detection II-71
Nanobiotechnology Enables SARS Test Development II-72

9. Product Introductions/Developments II-73
Evident Technologies Introduces Metal Quantum Dot Reagents II-73
Abraxis Oncology Launches Novel Abraxane Drug Delivery System II-73
Nanophase Introduces Novel Zinc Oxide Nanomaterial II-73
ANP Technologies Develops Innovative Biological Detection System II-73
Acrongenomics Introduces Innovative Cancer Detection Equipment II-74

10.Recent Industry Activity II-75
Invitrogen Acquires Quantum Dot Corporation II-75
NABsys and Brown University Forge Partnership II-75
University of Maryland Forges Partnership with University of
Maryland Biotechnology Institute II-75
ANP Technologies Partners with Cogent Systems II-75
NCI forms Strategic Partnership with NSF II-75
Debiopharm and Nanocarrier Ink Pact to Develop Platinum Anti
Cancer Product II-76
Capsulution and Ebara Sign Manufacturing Agreement for Nano-
capsules II-76
Invitrogen Licenses Nanoclusters Technology from Georgia Tech
Research II-76
Dendritic NanoTechnologies, Starpharma, and Dow Ink Pact II-76
Dendritic Nanotechnologies Inks Collaboration Pact with NCL II-76
Flamel Terminates Licensing Agreement with Biovail II-77
MFIC Corporation and University of Massachusetts Sign
Collaboration Pact II-77
TAP Delivers Notice to Terminate Licensing Agreement with Flamel II-77
Nanophase Inks Pact with Competitive Technologies II-77
Infectech Changes Name to Nanologix II-77
Arrowhead Establishes Nanobiotechnology Company II-78
NCI Grants Funds to Establish Centers of Cancer Nanotechnology
Excellence II-78
Capsulution Bags Patents to Develop and Market Nano and
Microstructures II-78
Capsulution Receives Patent for Production of Novel Nano and
Micro-Capsules II-78
Carbon Nanotechnologies Wins 30 Patents for Small-diameter
Carbon Nanotubes II-79
Adnavance Technologies Receives Funding for M-DNA Technology II-79
Angstrom Medica Wins FDA Approval for Nanoss™ Bone Void Filler II-79
Carbon Nanotechnologies and C Sixty Merge II-79
Capsulution and Nanosolutions to Join Forces II-79
UK Institutions Forge Partnership to Develop Novel Therapy
for Cancer II-80
Triton and XOMA Sign Licensing Agreement II-80
BioTrove Receives $11.1Million Funding to Develop
Nanobiotechnology Products II-80
Alnis Secures $2.71 Million Funding from NCI II-80
Invitrogen Acquires Genicons RLS Technology II-80
C Sixty Inks License, Option and Supply Agreement with Merck. II-81
Alnis Wins Health Contract Award from NCI II-81

11.Focus on Select Global Players II-82
Alnis Biosciences, Inc. (USA) II-82
American Pharmaceutical Partners, Inc. (USA) II-82
Biosante Phosphate Pharmaceuticals, Inc. (USA) II-82
Capsulution NanoScience AG (Germany) II-82
Carbon Nanotechnologies, Inc. (USA) II-83
C Sixty, Inc. (USA) II-83
Dendritic Nanotechnologies, Inc. (USA) II-83
Dendritech, Inc. (USA) II-83
Elan Pharmaceuticals (USA) II-84
Flamel Technologies, Inc. (France) II-84
iMedd, Inc. (USA) II-84
Nanospectra Biosciences, Inc. (USA) II-84
Nanophase Technologies Corporation (USA) II-84
Nano-C, Inc. (USA) II-85
Nanocyl SA (Belgium) II-85
Nanolab Systems Ltd. (Finland) II-85
Nanosphere, Inc. (USA) II-85
Nanotherapeutics, Inc. (USA) II-86
Nanosys, Inc. (USA) II-86
PSiVida Ltd (Australia) II-86
Quantum Dot Corp. (USA) II-86
Starpharma Holdings Ltd. (Australia) II-87
Sigma Aldrich Company (USA) II-87
Triton Biosystems, Inc (USA) II-87

12.Global Market Perspective II-88
Table 4: World Recent Past, Current & Future Analysis for
Nanobiotechnology by Geographic Region
USA, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-88

Table 5: World 10-Year Perspective for Nanobiotechnology by
Geographic Region
Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
(includes corresponding Graph/Chart) II-88

Table 6: World Recent Past, Current & Future Analysis for
Nanomaterials by Geographic Region
USA, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-89

Table 7: World 10-Year Perspective for Nanomaterials by
Geographic Region
Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
(includes corresponding Graph/Chart) II-89

Table 8: World Recent Past, Current & Future Analysis for
Solid Inorganic Nanoparticles by Geographic Region
USA,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2000 through 2010(includes corresponding Graph/Chart) II-90

Table 9: World 10-Year Perspective for Solid Inorganic
Nanoparticles by Geographic Region
Percentage Breakdown of
Revenues for USA, Japan, Europe, and Rest of World for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-90

Table 10: World Recent Past, Current & Future Analysis for
Nanocomposites by Geographic Region
USA, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-91

Table 11: World 10-Year Perspective for Nanocomposites by
Geographic Region
Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
(includes corresponding Graph/Chart) II-91

Table 12: World Recent Past, Current & Future Analysis for
Nanostructured Materials & Membranes by Geographic Region -
USA, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-92

Table 13: World 10-Year Perspective for Nanostructured
Materials & Membranes by Geographic Region
Percentage
Breakdown of Revenues for USA, Japan, Europe, and Rest of
World for Years 2000, 2005 & 2010 (includes corresponding
Graph/Chart) II-92

Table 14: World Recent Past, Current & Future Analysis for
Nanotubes and Fullerenes by Geographic Region
USA, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-93

Table 15: World 10-Year Perspective for Nanotubes and
Fullerenes by Geographic Region
Percentage Breakdown of
Revenues for USA, Japan, Europe, and Rest of World for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-93

Table 16: World Recent Past, Current & Future Analysis for
Other Nanomaterials by Geographic Region
USA, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-94

Table 17: World 10-Year Perspective for Other Nanomaterials
by Geographic Region
Percentage Breakdown of Revenues for
USA, Japan, Europe, and Rest of World for Years 2000, 2005 &
2010 (includes corresponding Graph/Chart) II-94

Table 18: World Recent Past, Current & Future Analysis for
Nanodevices/Tools by Geographic Region
USA, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-95

Table 19: World 10-Year Perspective for Nanodevices/Tools by
Geographic Region
Percentage Breakdown of Revenues for USA,
Japan, Europe, and Rest of World for Years 2000, 2005 & 2010
(includes corresponding Graph/Chart) II-95


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Industry Overview III-1
Public Sector Funding III-1
Major Nanobiotechnology Institutions and Centers III-2
The Nanobiotechnology Center (NBTC) III-2
Principal NBTC Partners III-3
Centre for Biologic Nanotechnology (CBN) III-3
Centre for Biological and Environmental Nanotechnology(CBEN) III-3
Regulatory Environment III-4
Technological Developments III-4
Product Introductions/Developments III-7
Strategic Corporate Developments III-8
Key Players III-12
B.Market Analytics III-17
Table 20: US Recent Past, Current & Future Analysis for
Nanobiotechnology by Technology Segment
Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-17

Table 21: US 10-Year Perspective for Nanobiotechnology by
Technology Segment -Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-18

2. Japan III-19
A.Market Analysis III-19
Outlook III-19
Public Sector Funding III-19
Technological Development III-19
B.Market Analytics III-20
Table 22: Japanese Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment
Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-20

Table 23: Japanese 10-Year Perspective for Nanobiotechnology
by Technology Segment
Percentage Breakdown of Revenues
for Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-21

3. Europe III-22
A.Market Analysis III-22
Outlook III-22
Market Overview III-22
European Union Banks Heavily on Nanobiotechnology III-22
Nano2Life Network III-23 Major Nanobiotechnology
Networks in Europe III-24
Public Sector Funding III-24
Table 24: European Nanobiotechnology Market (2003 & 2004):
Percentage Breakdown of Public Sector Funding by Leading
Region/Country
European Commission, Germany, France, UK,
and Others (includes corresponding Graph/Chart) III-25
Regulatory Environment III-25
Registration for Novel Nanobiotech Drugs Pose Major
Bottlenecks III-25
Focus on Select Markets III-26
Germany III-26
France III-26
United Kingdom III-26
Rest of Europe III-27
Ireland III-27
Market Overview III-27
Key Research Institutions/Centers in Nanobiotechnology III-28
The Tyndall National Institute III-28
The Centre for Research on Adaptive Nanostructures and
NanoDevices III-28
The National Centre for Sensor Research III-28
The Sami Nasr Institute for Advanced Materials Science III-28
Technological Developments III-29
Strategic Corporate Developments III-29
Key Players III-31
B.Market Analytics III-33
Table 25: European Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment
Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-33

Table 26: European 10-Year Perspective for Nanobiotechnology
by Technology Segment
Percentage Breakdown of Revenues
for Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-34

4. Rest of World III-35
A.Market Analysis III-35
Outlook III-35
Public Sector Funding III-35
Table 27: Nanobiotechnology Market in Rest of World (2004):
Percentage Breakdown of Public Sector Funding by Leading
Country
South Korea, Taiwan, China, Australia, Canada,
and Others (includes corresponding Graph/Chart) III-36
Focus on Select Markets III-36
Australia III-36
Market Overview III-36
Innovative Drug Delivery
A Key Focus Area for Major
Australian Companies III-36
Nanobiotechnology Offers Major Breakthrough in HIV Drug
Development III-37
Major Institution III-37
India III-38
Market Overview III-38
Korea III-38
Market Overview III-38
Table 28: Korean Nanobiotechnology Market (2003 & 2004):
Funding in US$ Million by Major Organization Type -
University Centers, Public Research Institution, and
Companies (includes corresponding Graph/Chart) III-39
Key Players III-39
B.Market Analytics III-40
Table 29: Rest of World Recent Past, Current & Future
Analysis for Nanobiotechnology by Technology Segment -
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-40

Table 30: Rest of World 10-Year Perspective for
Nanobiotechnology by Technology Segment
Percentage
Breakdown of Revenues for Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools for Years 2000, 2005 & 2010. (includes
corresponding Graph/Chart) III-41


IV. COMPETITION

1. Abraxis Bioscience, Inc. (USA) IV-1
Table 31: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-2

Table 32: First Quarter Sales Analysis by Product:
2005-2006 (Q1) (In US$ million) IV-2

Table 33: Annual Sales Analysis: 2003-2005 (In US$
million) IV-2
Abraxis Oncology (USA) IV-2
2. Acrongenomics, Inc. (Canada) IV-3
3. Ademtech SA (France) IV-4
4. Adnavance Technologies, Inc. (Canada) IV-5
5. Advanced Micro/Nano Devices Lab (Canada) IV-6
6. Advion Biosciences, Inc. (USA) IV-7
7. Albany Molecular Research, Inc. (USA) IV-8
Table 34: Annual Sales Analysis: 2003-2005 (In US$
million) IV-8
8. Alnis Biosciences, Inc. (USA) IV-11
9. Ambri Limited (Australia) IV-12
Table 35: Half Yearly Sales Analysis: 2005-2006 (H1)
(In A$ million) IV-13

Table 36: Annual Sales Analysis: 2004-2005 (In A$
million) IV-13

Table 37: Annual Sales Analysis: 2003-2004 (In A$
million) IV-13
10. Angstrom Medica, Inc. (USA) IV-14
11. ANP Technologies, Inc. (USA) IV-15
12. Arrowhead Research Corporation (USA) IV-16
Calando Pharmaceuticals, Inc. (USA) IV-16
13. Asklepios Biopharmaceutical, Inc. (USA) IV-17
14. BioDelivery Sciences International (USA) IV-18
Table 38: Annual Sales Analysis: 2004-2005 (In US$
million) IV-18
15. BioForce Nanosciences, Inc. (USA) IV-20
16. BioNano International Singapore Pte., Ltd. (Singapore) IV-21
17. Biophage Pharma, Inc. (Canada) IV-22
18. Biosante Pharmaceuticals, Inc. (USA) IV-24
Table 39: Annual Sales Analysis: 2003-2005 (In US$
thousand) IV-24

Table 40: Annual Sales Analysis by Quarter: 2004-2005
(In US$ thousand) IV-25
19. Biotrove, Inc. (USA) IV-26
20. Biovail Corporation (Canada) IV-28
Table 41: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-29

Table 42: Annual Sales Analysis: 2003-2005 (In US$
million) IV-30

Table 43: Annual Sales Analysis by Operation: 2004-2005
(In US$ million) IV-30

Table 44: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-30

Table 45: Annual Sales Analysis by Operation: 2003-2004
(In US$ million) IV-30

Table 46: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-30
21. Capsulution Nanoscience AG (Germany) IV-35
22. Carbon Nanotechnologies, Inc. (USA) IV-37
C Sixty, Inc. (USA) IV-39
23. Cogent Systems, Inc. (USA) IV-40
Table 47: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-40
Table 48: First Quarter Sales Analysis by Geographic
Region: 2005-2006 (Q1) (In US$ million) IV-41
Table 49: Annual Sales Analysis: 2003-2005 (In US$
million) IV-41

Table 50: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-41

Table 51: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-41
24. Competitive Technologies, Inc. (USA) IV-45
Table 52: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-45
Half Yearly Sales Analysis by Quarter: 2005-2006 (H1)
(In US$ million) IV-46
Table 53: Annual Sales Analysis: 2003-2005 (In US$
million) IV-46

Table 54: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-46

Table 55: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-46
25. Concentris GmbH (Switzerland) IV-48
26. Crystalplex Corporation (USA) IV-50
27. CytImmune Science, Inc. (USA) IV-51
28. Cytoplex Biosciences (USA) IV-52
29. Debiopharm SA (Switzerland) IV-53
30. Dendritech, Inc. (USA) IV-55
31. Dendritic Nanotechnologies, Inc. (USA) IV-56
32. Do-Coop Technologies Ltd. (Israel) IV-57
33. Dow Nanotechnology (USA) IV-58
34. Ebara Corporation (Japan) IV-59
Table 56: Annual Sales Analysis: 2003-2005 (In ¥
billion) IV-61

Table 57: Annual Sales Analysis by Segment: 2004-2005
(In ¥ billion) IV-61

Table 58: Annual Sales Analysis by Geographic Region:
2004-2005 (In ¥ billion) IV-61

Table 59: Annual Sales Analysis by Segment: 2003-2004
(In ¥ billion) IV-61

Table 60: Annual Sales Analysis by Geographic Region:
2003-2004 (In ¥ billion) IV-61
35. Eiffel Technologies Ltd. (Australia) IV-63
Table 61: Annual Sales Analysis: 2003-2005 (In US$
million) IV-63
36. Elan Corporation PLC (Ireland) IV-65
Table 62: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-66

Table 63: Annual Sales Analysis: 2003-2005 (In US$
million) IV-66

Table 64: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-66

Table 65: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-67

Table 66: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-67

Table 67: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-67
Elan Pharmaceuticals (USA) IV-69
37. Evident Technologies (USA) IV-70
38. Exqor (USA) IV-71
39. Flamel Technologies SA (France) IV-72
Table 68: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-73

Table 69: Annual Sales Analysis: 2003-2005 (In US$
million) IV-73

Table 70: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-73

Table 71: Annual Sales Analysis by Quarter: 2003-2004
(In US$ million) IV-73
40. Fluidigm Corporation (USA) IV-76
41. Genefluidics, Inc. (USA) IV-78
42. Genencor International, Inc. (USA) IV-79
Table 72: Annual Sales Analysis: 2003-2004 (In US$
million) IV-80

Table 73: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-80

Table 74: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-80
43. Georgia Tech Research Corporation (USA) IV-86
44. Imedd, Inc. (USA) IV-86
45. Integrated Nano-Technologies (USA) IV-87
46. Interdisciplinary Research Collaboration In
Bionanotechnology (IRC) (UK) IV-88
47. Invitrogen Corporation (USA) IV-89
Table 75: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-90

Table 76: Annual Sales Analysis: 2003-2005 (In US$
million) IV-90

Table 77: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-90
48. JPK Instruments AG (Germany) IV-96
49. Kereos, Inc. (USA) IV-98
50. Luna Innovations, Inc. (USA) IV-100
51. MagnaMedics GmbH IV-103
52. Merck & Co., Inc. (USA) IV-105
Table 78: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-106

Table 79: First Quarter Sales Analysis by Product:
2005-2006 (Q1) (In US$ million) IV-106

Table 80: Annual Sales Analysis: 2003-2005 (In US$
million) IV-106

Table 81: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-107

Table 82: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-107

Table 83: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-107

Table 84: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-108
53. MFIC Corporation (USA) IV-112
Table 85: Annual Sales Analysis: 2003-2005 (In US$
million) IV-112

Table 86: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-113

Table 87: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-113

Table 88: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-113

Table 89: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-113
54. Nabsys, Inc. (USA) IV-115
55. Nacbo (Italy) IV-115
56. Nano Interface Technology, Inc. (NITI) (USA) IV-116
57. NanoBioMagnetics, Inc. (USA) IV-116
58. NanoBioNexus (USA) IV-117
59. Nanobiosym, Inc. (USA) IV-118
60. Nano-C, Inc. (USA) IV-118
61. NanoCarrier Co., Ltd. (Japan) IV-119
62. Nanocyl SA (Belgium) IV-120
63. Nanodisc, Inc. (USA) IV-121
64. Nanodynamics, Inc. (USA) IV-122
65. NanoLab, Inc. (USA) IV-126
66. Nanolab Systems Ltd. (Finland) IV-126
67. Nanolight Technologies (USA) IV-127
68. Nanologix, Inc. (USA) IV-128
69. NanoNord A/S (Denmark) IV-129
70. Nanophase Technologies Corporation (USA) IV-130
Table 90: First Quarter Sales Analysis: 2005-2006
(Three Months Ended, March) (In US$ millions) IV-130

Table 91: First Quarter Sales Analysis By Operations:
2005-2006 (Three Months Ended, March) (In US$ millions) IV-131

Table 92: Annual Sales Analysis: 2003-2005 (In US$
millions) IV-131

Table 93: Annual Sales Analysis By Operations: 2004-
2005 (In US$ millions) IV-131

Table 94: Annual Sales Analysis By Operations: 2003-
2004 (In US$ millions) IV-131

Table 95: Quarterly Sales Analysis: 2004-2005 (In US$
millions) IV-131

Table 96: Quarterly Sales Analysis: 2003-2004 (In US$
millions) IV-132

71. Nanoplex Technologies, Inc. (USA) IV-135
72. Nanoprobes, Inc. (USA) IV-136
73. Nanosolutions GmbH (Germany) IV-137
74. Nanospectra Biosciences, Inc. (USA) IV-137
75. Nanosphere, Inc. (USA) IV-138
76. Nanosys, Inc. (USA) IV-139
77. Nanotherapeutics, Inc. (USA) IV-142
78. Nanoxis AB (Sweden) IV-143
79. National Physical Laboratory (UK) IV-144
80. Platypus Technologies, LLC (USA) IV-146
81. Proteinx Lab (USA) IV-147
82. PSiVida Ltd. (Australia) IV-148
83. Sigma-Aldrich Corporation (USA) IV-149
Table 97: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-150

Table 98: Annual Sales Analysis: 2003-2005 (In US$
million) IV-150

Table 99: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-150

Table 100: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-150

Table 101: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-151

Table 102: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-151

Table 103: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-151

Table 104: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-151
84. SRU Biosystems, Inc. (USA) IV-158
85. Starpharma Holdings Limited (Australia) IV-159
Table 105: Half Yearly Sales Analysis: 2005-2006 (H1)
(In A$ million) IV-159

Table 106: Annual Sales Analysis: 2003-2005 (In A$
million) IV-160

Table 107: Annual Sales Analysis by Segment: 2004-2005
(In A$ million) IV-160

Table 108: Annual Sales Analysis by Segment: 2003-2004
(In A$ million) IV-160
86. Tap Pharmaceutical Products, Inc. (USA) IV-162
87. Triton Biosystems, Inc. (USA) IV-163
88. U.S. Genomics, Inc. (USA) IV-164
89. Visigen Biotechnologies, Inc. (USA) IV-168
90. Vulvox Nano/Biotechnology Corporation (USA) IV-169
91. Xoma Ltd. (USA) IV-170
Table 109: Annual Sales Analysis: 2004-2005 (In US$
thousand) IV-170

Table 110: Annual Sales Analysis by Segment: 2004-2005
(In US$ thousand) IV-170

Table 111: Annual Sales Analysis by Geographical
Region: 2004-2005 (In US$ thousand) IV-170